Watch VRDN. Know when insiders buy.
One email the day a filing lands. Free.
VRDN
Viridian Therapeutics, Inc.
23.01
+0.58 +2.59%
USD · close Oct 21
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
40
WATCH · insiders 35, shorts 44
Insiders, 90 days
−$348K
net selling · 0 buys, 2 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $2.6BP/E —DIV YIELD —FCF YIELD -12.85%REV TTM —NET INCOME −$387MNET CASH $4.5M52W 13.30 – 33.78SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$126.3M | −$127.1M | — | — | −$105.3M | $1.3M | −$106.6M | Aug 6 |
| Q1 2026 · Mar 31 | — | — | — | −$116.2M | −$104.9M | — | — | −$119.7M | $23K | −$119.7M | Aug 6 |
| Q4 2025 · Dec 31derived | — | — | — | −$122.7M | −$120.4M | — | — | −$23.8M | $240K | −$24M | Feb 26 |
| Q3 2025 · Sep 30 | — | — | — | −$40M | −$34.6M | — | — | −$84.6M | $127K | −$84.7M | Nov 5 |
| Q2 2025 · Jun 30 | — | — | — | −$106.8M | −$100.7M | — | — | −$75.4M | $42K | −$75.4M | Aug 6 |
| Q1 2025 · Mar 31 | — | — | — | −$93.9M | −$86.9M | — | — | −$92.7M | $86K | −$92.7M | Aug 6 |
| Q4 2024 · Dec 31derived | — | — | — | −$87.5M | −$79.7M | — | — | −$73.3M | $114K | −$73.4M | Feb 26 |
| Q3 2024 · Sep 30 | — | — | — | −$83.5M | −$76.7M | — | -1.15 | −$67.7M | $293K | −$68M | Nov 5 |
| Q2 2024 · Jun 30 | — | — | — | −$72.2M | −$65M | — | -1.02 | −$46.1M | $104K | −$46.2M | Nov 5 |
| Q1 2024 · Mar 31 | — | — | — | −$55.9M | −$48.5M | — | -0.79 | −$45.2M | $0 | −$45.2M | Nov 5 |
| Q4 2023 · Dec 31derived | — | — | — | −$71.5M | −$66.9M | — | -1.34 | −$38M | $48K | −$38M | Feb 26 |
| Q3 2023 · Sep 30 | — | — | — | −$51.2M | −$47.7M | — | -1.09 | −$39M | $404K | −$39.4M | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$363.4M | −$342.6M | — | — | −$276.4M | $495K | −$276.9M | — | — |
| FY2024 · to Dec 31 | — | — | −$299M | −$269.9M | — | — | −$232.3M | $511K | −$232.8M | — | — |
| FY2023 · to Dec 31 | — | — | −$254.4M | −$237.7M | — | -5.31 | −$184.2M | $898K | −$185.1M | — | — |
| FY2022 · to Dec 31 | — | — | −$134.3M | −$129.9M | — | -4.05 | −$93.8M | $797K | −$94.6M | — | — |
| FY2021 · to Dec 31 | — | — | −$79.7M | −$79.4M | — | -6.66 | −$54.6M | $338K | −$54.9M | — | — |
| FY2020 · to Dec 31 | — | — | −$110.4M | −$110.7M | — | -31.13 | −$29.8M | $42K | −$29.8M | — | — |
Every number comes from Viridian Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.